Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $284
BeiGene Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Coverage On BeiGene With Market Outperform Rating, Announces Price Target of $288
BeiGene Analyst Ratings
JMP Securities Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $288
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Maintains Target Price $198
Hold Rating on BeiGene Amid Mixed Sales Performance and Competitive Pressures
Morgan Stanley Maintains BeiGene(BGNE.US) With Buy Rating, Cuts Target Price to $307
Morgan Stanley Maintains BeiGene(BGNE.US) With Buy Rating, Cuts Target Price to $307
BeiGene Analyst Ratings
J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $200
TD Cowen Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $254
TD Cowen Sticks to Its Buy Rating for BeiGene (BGNE)
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $284
Jefferies Sticks to Their Buy Rating for BeiGene (BGNE)
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $198
Hold Rating on BeiGene Amid Mixed Drug Performance and Strong Pipeline Potential
BeiGene's Strong Financial and Clinical Prospects Solidify Buy Rating
BeiGene Analyst Ratings